Uptrend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend up since Sep 16 · above the Ichimoku cloud · RSI 43 · MACD below its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.2M | 0.00% | 169.40K | +120% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NRXS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 7, 2026 | Carrico Thomas JoesephOfficer | Purchase at price 6.83 per share. | 328 | $2.24K |
| Oct 7, 2026 | Carrico Brian AllenChief Executive Officer | Purchase at price 6.83 per share. | 268 | $1.83K |
| Oct 7, 2026 | Henrichs Timothy RobertChief Financial Officer | Purchase at price 6.83 per share. | 1.9K | $13.23K |
| Aug 23, 2026 | Carrico Thomas JoesephOfficer | Conversion of Exercise of derivative security at price 6.94 per share. | 306.2K | $2.13M |
| Aug 23, 2026 | Carrico Brian AllenChief Executive Officer | Conversion of Exercise of derivative security at price 6.94 per share. | 320K | $2.22M |
| Aug 23, 2026 | Miranda AdrianOfficer | Conversion of Exercise of derivative security at price 6.94 per share. | 337.2K | $2.34M |
| Aug 23, 2026 | Carrico Thomas JoesephOfficer | Stock Award(Grant) at price 0.00 per share. | 193.7K | — |
| Aug 23, 2026 | Carrico Brian AllenChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 199.2K | — |
| Aug 23, 2026 | Miranda AdrianOfficer | Stock Award(Grant) at price 0.00 per share. | 199.1K | — |
| Aug 12, 2026 | Ferge Kristin ADirector | Stock Award(Grant) at price 6.28 per share. | 31.1K | $195.52K |
| Aug 12, 2026 | Aharon Gilad S.Director | Stock Award(Grant) at price 0.00 - 6.28 per share. | 86.2K | $275.88K |
| Aug 12, 2026 | Watkins Bradley MitchellDirector | Stock Award(Grant) at price 6.28 per share. | 26.1K | $163.74K |
| Aug 12, 2026 | Keyser Jane ElizabethDirector | Stock Award(Grant) at price 6.28 per share. | 26.1K | $163.74K |
| Apr 27, 2026 | Aharon Gilad S.Director | Stock Award(Grant) at price 0.00 per share. | 234.2K | — |
| Mar 31, 2026 | Carrico Thomas JoesephOfficer | Purchase at price 7.18 per share. | 667 | $4.79K |
| Mar 31, 2026 | Carrico Brian AllenChief Executive Officer | Purchase at price 7.18 per share. | 8.1K | $57.87K |
| Mar 31, 2026 | Henrichs Timothy RobertChief Financial Officer | Purchase at price 7.18 per share. | 7.6K | $54.52K |
| Feb 11, 2026 | Hannasch BrianBeneficial Owner of more than 10% of a Class of Security | Purchase at price 4.65 - 4.92 per share. | 80K | $382.80K |
| Jan 21, 2026 | Ferge Kristin ADirector | Stock Award(Grant) at price 4.63 per share. | 21.6K | $100.00K |
| Jan 21, 2026 | Aharon Gilad S.Director | Stock Award(Grant) at price 4.63 per share. | 21.6K | $100.00K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.8 | 41.8 | 23.3 | 0.7 | -0.5 | -1.3 | -14.5 | -3.8 | 22.6 | -11.4 | +43.8% | ||
| 2025 | 6.4 | -12.8 | -1.4 | 9.3 | 16.2 | -11.4 | 8.3 | -3.1 | 21.3 | -11.7 | 2.2 | 63.3 | +93.2% |
| 2024 | -6.4 | 39.6 | -10.6 | 2.6 | 1.2 | -14.2 | 16.5 | -5.6 | -2.6 | -9.7 | 10.5 | -21.0 | −12.0% |
| 2023 | -10.8 | -50.0 | 66.3 | -15.5 | −37.3% |
Buy / hold / sell counts
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.